NCEL · NewcelX Ltd.

Summary

NewcelX Ltd. announced a collaborative research agreement with Eledon Pharmaceuticals, Inc. to advance its lead program NCEL-101 for Type 1 Diabetes by integrating stem-cell-derived islets with Eledon's investigational anti-CD40L monoclonal antibody tegoprubart. The collaboration leverages Eledon's clinical experience from over 100 transplant patients to support durable graft survival and a potential functional cure.

Key takeaways

• Strategic collaboration with Eledon Pharmaceuticals (Nasdaq: ELDN)
• Advances NCEL-101 program integrating with tegoprubart (AT-1501)
• Eledon has treated over 100 transplant patients under multiple FDA-cleared IND applications
• NCEL-101 is NewcelX's core stem-cell-derived therapy for Type 1 Diabetes
• Quotes from CSO Michel Revel and CEO Ronen Twito highlight strategic milestone and regulatory pathway benefits